BIO 300

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

About Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

Therapeutic Areas